FINWIRES · TerminalLIVE
FINWIRES

Markets Remain "Cautiously" Optimistic on Iran War Deal, Says Scotiabank

作者

-- Markets continue to be "cautiously" optimistic on Thursday toward the prospect of a United States-Iran deal to end the war despite the appearances of the U.S. administration pumping the deal vastly more than the other side, said Scotiabank.

Oil is off by another couple of US dollars a barrel early Thursday, noted the bank.

Sovereign yields are slightly lower by 1bps to 2bps across major markets, stated Scotiabank. The US dollar (USD) is on the run, but with Norway's krone (NOK) outperforming after the central bank hiked.

Equities are mixed, however, with North American futures in the black but European cash markets slightly in the red, added Scotiabank.

Any hints at which direction negotiations are going will clearly dominate market movements relative to what else is on the line-up in the macroeconomics calendar, according to the bank.

相关文章

Insider Trading

根据最近提交给美国证券交易委员会(SEC)的文件显示,康斯坦利姆公司内部人士出售了价值822,057美元的股票。

2026年5月5日,执行副总裁兼首席财务官郭杰克(Jack Q. Guo)出售了Constellium (CSTM)的25,201股股票,套现822,057美元。根据向美国证券交易委员会(SEC)提交的4号表格文件,郭杰克目前控制着该公司共计185,368股普通股,其中185,368股为直接持有。 SEC文件链接: https://www.sec.gov/Archives/edgar/data/1563411/000209518226000002/xslF345X05/wk-form4_1778162530.xmlPrice: $33.06, Change: $-0.27, Percent Change: -0.83%

$CSTM
Asia

最新消息:武汉益智生物制药有限公司(隶属于中国生物制药集团)的腹水药物申请已获中国受理。

(更新内容包括该药物的主要研发方武汉益智生物制药) 武汉益智生物制药(港交所代码:2496)与中国生物制药(港交所代码:1177)旗下子公司共同研发的药物M701的新药申请已获中国国家药品监督管理局受理。 根据周四在香港交易所提交的两份文件显示,该药物用于治疗晚期上皮恶性肿瘤引起的恶性腹水。 中国生物制药旗下子公司正泰天青药业集团于2024年8月获得该药物在中国大陆的独家可转授许可,负责该药物的注册、研发、生产和销售。

$HKG:1177$HKG:2496
International

3月份美国建筑支出增幅超出预期,住宅建设增加

美国3月份建筑支出增长0.6%,高于彭博社此前调查预测的0.2%的增幅,而2月份则下降了0.2%。 私人住宅建设增长1.7%,其中独栋住宅建设增长2.7%,多户住宅建设增长0.3%,房屋改造增长0.9%。 私人非住宅建设和公共建设均下降0.2%。